Significant improvement of bone marrow-derived MSC expansion from MDS patients by defined xeno-free medium.
Bone marrow-derived mesenchymal stromal cells
Myelodysplastic Neoplasms
Xeno-free expansion
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
07 06 2023
07 06 2023
Historique:
received:
03
06
2022
accepted:
24
05
2023
medline:
9
6
2023
pubmed:
8
6
2023
entrez:
7
6
2023
Statut:
epublish
Résumé
Robust and reliable in vitro and in vivo models of primary cells are necessary to study the pathomechanisms of Myelodysplastic Neoplasms (MDS) and identify novel therapeutic strategies. MDS-derived hematopoietic stem and progenitor cells (HSPCs) are reliant on the support of bone marrow (BM) derived mesenchymal stroma cells (MSCs). Therefore, isolation and expansion of MCSs are essential for successfully modeling this disease. For the clinical use of healthy MSCs isolated from human BM, umbilical cord blood or adipose tissue, several studies showed that xeno-free (XF) culture conditions resulted in superior growth kinetics compared to MSCs cultured in the presence of fetal bovine serum (FBS). In this present study, we investigate, whether the replacement of a commercially available MSC expansion medium containing FBS with a XF medium is beneficial for the expansion of MSCs derived from BM of MDS patients which are often difficult to cultivate. MSCs isolated from BM of MDS patients were cultured and expanded in MSC expansion medium with FBS or XF supplement. Subsequently, the impact of culture media on growth kinetics, morphology, immunophenotype, clonogenic potential, differentiation capacity, gene expression profiles and ability to engraft in immunodeficient mouse models was evaluated. Significant higher cell numbers with an increase in clonogenic potential were observed during culture of MDS MSCs with XF medium compared to medium containing FBS. Differential gene expression showed an increase in transcripts associated with MSC stemness after expansion with XF. Furthermore, immunophenotypes of the MSCs and their ability to differentiate into osteoblasts, adipocytes or chondroblasts remained stable. MSCs expanded with XF media were similarly supportive for creating MDS xenografts in vivo as MSCs expanded with FBS. Our data indicate that with XF media, higher cell numbers of MDS MSCs can be obtained with overall improved characteristics in in vitro and in vivo experimental models.
Sections du résumé
BACKGROUND
Robust and reliable in vitro and in vivo models of primary cells are necessary to study the pathomechanisms of Myelodysplastic Neoplasms (MDS) and identify novel therapeutic strategies. MDS-derived hematopoietic stem and progenitor cells (HSPCs) are reliant on the support of bone marrow (BM) derived mesenchymal stroma cells (MSCs). Therefore, isolation and expansion of MCSs are essential for successfully modeling this disease. For the clinical use of healthy MSCs isolated from human BM, umbilical cord blood or adipose tissue, several studies showed that xeno-free (XF) culture conditions resulted in superior growth kinetics compared to MSCs cultured in the presence of fetal bovine serum (FBS). In this present study, we investigate, whether the replacement of a commercially available MSC expansion medium containing FBS with a XF medium is beneficial for the expansion of MSCs derived from BM of MDS patients which are often difficult to cultivate.
METHODS
MSCs isolated from BM of MDS patients were cultured and expanded in MSC expansion medium with FBS or XF supplement. Subsequently, the impact of culture media on growth kinetics, morphology, immunophenotype, clonogenic potential, differentiation capacity, gene expression profiles and ability to engraft in immunodeficient mouse models was evaluated.
RESULTS
Significant higher cell numbers with an increase in clonogenic potential were observed during culture of MDS MSCs with XF medium compared to medium containing FBS. Differential gene expression showed an increase in transcripts associated with MSC stemness after expansion with XF. Furthermore, immunophenotypes of the MSCs and their ability to differentiate into osteoblasts, adipocytes or chondroblasts remained stable. MSCs expanded with XF media were similarly supportive for creating MDS xenografts in vivo as MSCs expanded with FBS.
CONCLUSION
Our data indicate that with XF media, higher cell numbers of MDS MSCs can be obtained with overall improved characteristics in in vitro and in vivo experimental models.
Identifiants
pubmed: 37287056
doi: 10.1186/s13287-023-03386-5
pii: 10.1186/s13287-023-03386-5
pmc: PMC10249283
doi:
Substances chimiques
Culture Media, Serum-Free
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
156Informations de copyright
© 2023. The Author(s).
Références
Blood Cancer Discov. 2021 Mar;2(2):135-145
pubmed: 33778768
Nat Commun. 2021 Oct 25;12(1):6170
pubmed: 34697318
N Engl J Med. 2020 Oct 1;383(14):1358-1374
pubmed: 32997910
Cytotherapy. 2009;11(7):958-72
pubmed: 19903107
J Immunol. 2005 May 15;174(10):6477-89
pubmed: 15879151
Stem Cell Res Ther. 2019 Aug 5;10(1):235
pubmed: 31383013
Int J Reprod Biomed. 2016 Sep;14(9):567-576
pubmed: 27738658
Leukemia. 2013 Sep;27(9):1841-51
pubmed: 23797473
NPJ Regen Med. 2019 Dec 2;4:22
pubmed: 31815001
Haematologica. 2007 Sep;92(9):1208-15
pubmed: 17666368
Curr Hematol Malig Rep. 2015 Sep;10(3):272-81
pubmed: 26134527
J Biol Chem. 2017 May 12;292(19):7745-7760
pubmed: 28325836
Cell Stem Cell. 2014 Jun 5;14(6):824-37
pubmed: 24704494
Leukemia. 2022 Jul;36(7):1703-1719
pubmed: 35732831
J Cell Physiol. 2007 Oct;213(1):18-26
pubmed: 17458897
Sci Rep. 2015 Nov 13;5:16570
pubmed: 26564250
Stem Cell Res Ther. 2014 Jul 28;5(4):88
pubmed: 25069491
Int J Dev Biol. 2008;52(8):1033-42
pubmed: 18956336
Science. 1997 Apr 4;276(5309):71-4
pubmed: 9082988
Blood. 2014 Oct 30;124(18):2793-803
pubmed: 25237199
Blood. 2017 Mar 23;129(12):1617-1626
pubmed: 28159735
Stem Cells Dev. 2016 Apr 1;25(7):530-41
pubmed: 26879149
Int J Hematol. 2012 Jan;95(1):17-25
pubmed: 22218882
Tissue Eng Part A. 2010 Nov;16(11):3467-84
pubmed: 20572797
Front Cell Dev Biol. 2021 Feb 11;8:617466
pubmed: 33644035
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Haematologica. 2013 Nov;98(11):1677-85
pubmed: 23716561
Blood. 2012 Sep 20;120(12):2454-65
pubmed: 22740453
Leukemia. 2019 Jun;33(6):1487-1500
pubmed: 30575819
Leukemia. 2018 Aug;32(8):1679-1696
pubmed: 29946191
Biomed Res Int. 2014;2014:508216
pubmed: 24724084
ALTEX. 2018;35(1):99-118
pubmed: 28800376
Int J Biol Sci. 2015 Feb 05;11(3):324-34
pubmed: 25678851
Blood. 2019 Mar 7;133(10):1031-1038
pubmed: 30670448
Leukemia. 2022 Jan;36(1):236-247
pubmed: 34172896
Am J Hematol. 2012 Jul;87(7):692-701
pubmed: 22696212
Cancer. 2008 Sep 15;113(6):1351-61
pubmed: 18618511
Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7841-5
pubmed: 11427725
Blood. 2022 Sep 15;140(11):1200-1228
pubmed: 35767897